CANbridge Pharmaceuticals Inc. (1228) AI Stock Analysis

• Market Cap: HK$1.28B
• Dividend Yield: N/A
• Average Volume (3M): 5.03M
• Price to Earnings (P/E): 0.9
• Beta (1Y): 1.22
• Revenue Growth: -40.24%
• EPS Growth: 66.43%
• Country: HK
• Employees: 67
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 511,252,230
• 10 Day Avg. Volume: 2,153,700
• 30 Day Avg. Volume: 5,027,972
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.11
• Price to Sales (P/S): 0.62
• P/FCF Ratio: -0.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.67
• Revenue Forecast (FY): HK$299.65M

• Rating: 48 Neutral
• Price Target: HK$2.50 ▼(-0.79% Downside)
• Action: Downgraded Date: 01/27/26
• Date: Action: Downgraded 01/27/26

The score is primarily held back by weak financial performance (losses, negative equity, and negative cash flows). Technicals are comparatively strong with bullish trend/momentum, but valuation support is limited given the negative P/E and lack of dividend yield data.

Positive Factors

Focus on rare diseases and oncology

Targeting rare diseases and oncology is a durable strategic position: these areas have persistent unmet medical need, regulatory incentives, and potential for premium pricing. Success in these niches can create long-term, high-value revenue streams and durable market exclusivity.

Multiple funding and partnership channels

A diversified funding model — product sales plus partnerships, upfronts, milestones and royalties — structurally reduces single-source revenue risk, enables milestone-driven non-dilutive funding, and supports sustained development and commercialization if partnerships are executed.

Positive gross profit margins

Positive gross margins indicate underlying product economics that could scale profitably once fixed R&D and SG&A are spread over higher revenue. If clinical candidates commercialize, this structural margin base supports sustainable operating profit improvement over the medium term.

Negative Factors

Negative equity and high leverage

Negative equity and high leverage are structural weaknesses: they limit borrowing capacity, raise refinancing risk, and constrain strategic flexibility. Long-term recovery requires substantial earnings improvement or capital raises, both of which can be difficult in volatile markets.

Persistently negative operating and free cash flow

Consistent negative operating and free cash flow forces ongoing reliance on external financing, increasing dilution risk and potentially delaying development timelines. Durable financial health requires a structural turnaround in cash generation or secured long-term funding sources.

Declining and inconsistent revenue trend

A steep, inconsistent revenue decline undermines the company's ability to scale and absorb fixed costs. Sustained negative top-line trends increase pressure on liquidity and raise execution risk for bringing pipeline products to market without steady commercial traction or larger partner support.

CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model

Company Description

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.

How the Company Makes Money

CANbridge Pharmaceuticals generates revenue through multiple channels, primarily by developing and commercializing its proprietary drug candidates, which are in various stages of clinical trials. The company may earn income from product sales once its drugs receive regulatory approval and are launched in the market. Additionally, CANbridge often engages in strategic partnerships and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments tied to developmental achievements, and royalties on future sales. These partnerships not only provide funding but also enhance the company's capability to bring its products to market more efficiently. Furthermore, CANbridge may benefit from government grants or incentives aimed at fostering innovation in the healthcare sector, particularly for treatments addressing rare diseases.

CANbridge Pharmaceuticals Inc. Financial Statement Overview

Summary

Weak fundamentals: declining/inconsistent revenue, significant net losses, negative equity with high leverage risk, and persistently negative operating/free cash flow indicating reliance on external financing.

Income Statement

The company shows a declining revenue trend with significant net losses. Gross profit margins are positive but are overshadowed by high negative EBIT and net profit margins due to substantial expenditures. Revenue growth has been inconsistent, demonstrating challenges in achieving sustainable growth in a competitive industry.

Balance Sheet

The company's balance sheet reflects high leverage with negative equity, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a risk in volatile markets. Despite a relatively low asset base, the company struggles with substantial liabilities, indicating potential liquidity issues.

Cash Flow

Operating and free cash flows are consistently negative, indicating challenges in generating positive cash flow from operations. The company's reliance on external financing is evident, and the cash flow to net income ratios highlight inefficiencies in converting profits into cash, exacerbating financial strain.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.56M	85.10M	102.87M	78.97M	31.16M	12.03M
Gross Profit	40.29M	54.30M	64.16M	48.89M	18.78M	6.88M
EBITDA	-150.16M	-328.69M	-341.43M	-454.63M	-1.06B	-824.41M
Net Income	-136.11M	-442.62M	-378.84M	-483.48M	-1.08B	-846.04M
Balance Sheet
Total Assets	105.50M	116.81M	395.36M	702.04M	892.52M	586.36M
Cash, Cash Equivalents and Short-Term Investments	1.96M	10.50M	137.49M	451.16M	745.82M	360.80M
Total Debt	34.97M	135.78M	141.93M	155.28M	52.10M	46.90M
Total Liabilities	514.58M	591.30M	435.15M	393.49M	199.13M	2.33B
Stockholders Equity	-409.08M	-474.49M	-39.79M	308.56M	693.39M	-1.75B
Cash Flow
Free Cash Flow	-14.19M	-122.50M	-319.09M	-315.76M	-592.40M	-305.13M
Operating Cash Flow	-14.10M	-122.39M	-278.23M	-280.98M	-587.07M	-151.65M
Investing Cash Flow	-38.00K	13.93M	-26.86M	-34.79M	126.09M	-153.48M
Financing Cash Flow	0.00	-18.57M	-28.02M	-20.70M	854.31M	679.26M

CANbridge Pharmaceuticals Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.52
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Neutral. The current price of 2.52 is below the 20-day moving average (MA) of 2.76, below the 50-day MA of 2.60, and above the 200-day MA of 1.85, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 42.65 is Neutral, neither overbought nor oversold. The STOCH value of 14.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1228.

CANbridge Pharmaceuticals Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2197	52 Neutral	HK$2.84B	-0.82	54.43%	―	79.98%	-3.40%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1228	48 Neutral	HK$1.28B	0.95	―	―	-40.24%	66.43%
9939	48 Neutral	HK$1.98B	-1.67	-54.87%	―	―	81.67%
2257	44 Neutral	HK$719.77M	-3.65	―	―	―	83.89%
6628	43 Neutral	HK$1.07B	-2.47	-34.18%	―	-57.84%	24.58%
2126	41 Neutral	HK$820.45M	-1.01	-59.45%	―	2.45%	2.58%

CANbridge Pharmaceuticals Inc. Corporate Events

CANbridge Grants Share Options and RSUs Equal to 1.25% of Share Capital

CANbridge Pharmaceuticals has granted 6,372,575 share options to 30 grantees and an equal number of restricted share units (RSUs) to 28 grantees under its post-IPO incentive schemes, representing about 1.25% of its issued share capital. The share options, which include awards to directors, service providers and non-connected employees, carry an exercise price of HK$2.32 per share and vest over time and upon meeting specific performance milestones such as license-out deals, commercial sales targets and financing achievements, underscoring the company’s use of equity incentives to drive long-term performance and retain key talent.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

CANbridge’s CAN 103 Gains Inclusion in China’s Innovative Drug List

CANbridge Pharmaceuticals Inc. announced that its enzyme replacement therapy, CAN 103, has been included in China’s first ‘Commercial Health Insurance Innovative Drug List,’ effective January 1, 2026. This inclusion marks a significant milestone for the company, as it ensures broader treatment coverage for Gaucher disease patients and enhances medication accessibility. The move is part of the company’s strategy to deepen its domestic R&D and commercialization efforts, supported by China’s healthcare security system.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

CANbridge Pharmaceuticals Secures Shareholder Approval for Key Resolutions at EGM

CANbridge Pharmaceuticals Inc. announced that all resolutions proposed at their Extraordinary General Meeting (EGM) held on December 4, 2025, were passed by shareholders. The resolutions included granting a new general mandate to the company’s directors to issue shares and extending this mandate to shares repurchased by the company. This approval reflects strong shareholder support and may enhance the company’s financial flexibility, potentially impacting its strategic initiatives and market positioning.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

CANbridge Pharmaceuticals to Hold Virtual EGM for Share Issuance Mandate

CANbridge Pharmaceuticals Inc. announced an extraordinary general meeting (EGM) to be held virtually on December 4, 2025. The meeting will address resolutions including the revocation of the existing general mandate for issuing shares and the approval of a new mandate allowing directors to issue additional shares up to 20% of the total shares in issue. This strategic move is aimed at enhancing the company’s flexibility in capital management and potentially strengthening its market position.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

CANbridge Pharmaceuticals Announces EGM and Register Closure

CANbridge Pharmaceuticals Inc. announced the closure of its register of members in preparation for an extraordinary general meeting (EGM) scheduled for December 4, 2025. This meeting is significant for shareholders as it determines their eligibility to attend and vote, impacting the company’s governance and strategic decisions. The closure period is from December 1 to December 4, 2025, and shareholders must ensure their shares are registered by November 28, 2025, to participate. This announcement underscores the company’s commitment to structured shareholder engagement and could influence its operational and strategic direction.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

CANbridge Pharmaceuticals Proposes New General Mandate for Share Issuance

CANbridge Pharmaceuticals Inc. has announced a proposal to refresh its Existing General Mandate, allowing directors to issue new shares up to 20% of the company’s issued share capital. This move comes after the full utilization of the existing mandate, and aims to provide the company with greater flexibility in managing its capital structure, potentially impacting its market positioning and offering new opportunities for investment.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.